We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Artivion (AORT - Free Report) shares soared 5.3% in the last trading session to close at $35.22. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.3% loss over the past four weeks.
Artivion saw a strong price increase on investors’ optimism driven by the news of the FDA’s premarket approval for the NEXUS Aortic Arch System, developed by Endospan Ltd., its long-standing partner. The approval entitles Artivion to exercise its option to acquire Endospan at any time within 90 days of receiving this notice of FDA approval.
This biological medical device maker is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $115.95 million, up 17.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Artivion, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AORT going forward to see if this recent jump can turn into more strength down the road.
Artivion is part of the Zacks Medical - Instruments industry. Treace Medical Concepts (TMCI - Free Report) , another stock in the same industry, closed the last trading session 6.9% lower at $1.34. TMCI has returned -12.7% in the past month.
For Treace Medical Concepts, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.27. This represents a change of -8% from what the company reported a year ago. Treace Medical Concepts currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?
Artivion (AORT - Free Report) shares soared 5.3% in the last trading session to close at $35.22. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.3% loss over the past four weeks.
Artivion saw a strong price increase on investors’ optimism driven by the news of the FDA’s premarket approval for the NEXUS Aortic Arch System, developed by Endospan Ltd., its long-standing partner. The approval entitles Artivion to exercise its option to acquire Endospan at any time within 90 days of receiving this notice of FDA approval.
This biological medical device maker is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $115.95 million, up 17.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Artivion, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AORT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Artivion is part of the Zacks Medical - Instruments industry. Treace Medical Concepts (TMCI - Free Report) , another stock in the same industry, closed the last trading session 6.9% lower at $1.34. TMCI has returned -12.7% in the past month.
For Treace Medical Concepts, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.27. This represents a change of -8% from what the company reported a year ago. Treace Medical Concepts currently has a Zacks Rank of #3 (Hold).